Janux Therapeutics, Inc.(JANX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

JANX Janux Therapeutics, Inc.

盘前交易 03-02 09:06:44 EST

13.61

-0.19

-1.38%

盘前13.61

+0.000.00%

08:41 EST

最高13.87	最低13.40	成交量86.13万
今开13.58	昨收13.80	日振幅3.40%
总市值8.28亿	流通市值5.67亿	总股本6,083万
成交额1,173万	换手率2.07%	流通股本4,168万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"JANX","market":"US","secType":"STK","nameCN":"Janux Therapeutics, Inc.","latestPrice":13.61,"timestamp":1772226000000,"preClose":13.8,"halted":0,"volume":861275,"hourTrading":{"tag":"盘前","latestPrice":13.61,"preClose":13.61,"latestTime":"08:41 EST","volume":6192,"amount":83734.682256,"timestamp":1772458884338,"change":0,"changeRate":0,"amplitude":0.030125},"delay":0,"changeRate":-0.013768115942029077,"floatShares":41680600,"shares":60831656,"eps":-1.833637,"marketStatus":"盘前交易","change":-0.19,"latestTime":"03-02 09:06:44 EST","open":13.58,"high":13.87,"low":13.4014,"amount":11727679.367475001,"amplitude":0.033957,"askPrice":13.8,"askSize":1,"bidPrice":12.04,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.833637,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772461800000},"marketStatusCode":1,"adr":0,"listingDate":1623384000000,"exchange":"NASDAQ","adjPreClose":13.61,"preHourTrading":{"tag":"盘前","latestPrice":13.61,"preClose":13.61,"latestTime":"08:41 EST","volume":6192,"amount":83734.682256,"timestamp":1772458884338,"change":0,"changeRate":0,"amplitude":0.030125},"postHourTrading":{"tag":"盘后","latestPrice":13.61,"preClose":13.61,"latestTime":"19:36 EST","volume":58913,"amount":801808.7596,"timestamp":1772239006857,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0853079960691865,"impliedVol":0.635,"impliedVolPercentile":0.052},"requestUrl":"/m/hq/s/JANX","defaultTab":"news","newsList":[{"id":"2605149493","title":"生物制药公司Janux Therapeutics与施贵宝达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2605149493","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605149493?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:47","pubTimestamp":1769089661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LENZ","IE00B2B36J28.USD","IE0009355771.USD","LU1868837300.USD","LU0096364046.USD","IE00BFXG1179.USD","LU1323610961.USD","BK4585","JANX","LU1989771016.USD","IE00BJJMRZ35.SGD","BMY","LU0225771236.USD","LU1291159041.SGD","LU1718418525.SGD","LU2242646821.SGD","LU2242652126.USD","LU1670710588.SGD","LU1868837136.USD","LU1571399168.USD","BK4007","LU0321505439.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0306806265.USD","BK4139","LU0061475181.USD","LU1868836914.USD","LU0225284248.USD","LU1868836591.USD","LU0237698245.USD","LU0306807586.USD","LU1074936037.SGD","LU0985481810.HKD","LU1670711123.USD","LU1430594728.SGD","LU0456855351.SGD","LU1261432733.SGD","LU1093756325.SGD","LU2125154935.USD","LU1585245621.USD","BK4559","LU0868494617.USD","LU1670710661.SGD","LU0114720955.EUR","BK4588","IE00BSNM7G36.USD","BK4539","BK4534","LU1093756168.USD"],"gpt_icon":0},{"id":"1150021627","title":"Janux Therapeutics股价盘前飙升14.5% 与百时美施贵宝达成癌症药物开发全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1150021627","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150021627?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:16","pubTimestamp":1769084184,"startTime":"0","endTime":"0","summary":"Janux Therapeutics, Inc. (JANX) 股价在盘前交易中大幅跃升14.5%，此前该公司宣布与制药巨头百时美施贵宝（Bristol Myers Squibb）就癌症药物开发项目达成了一项全球授权协议。\n此项合作旨在利用Janux Therapeutics的创新技术平台，共同推进新型癌症疗法的研发进程。市场对此消息反应积极，显示出投资者对此次强强联合及其在肿瘤治疗领域潜力的高度认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JANX"],"gpt_icon":0},{"id":"1106509089","title":"Janux Therapeutics与百时美施贵宝达成合作：后者将主导新药临床试验申请及后续全球开发商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1106509089","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106509089?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:09","pubTimestamp":1769083778,"startTime":"0","endTime":"0","summary":"根据最新合作协议框架，Janux Therapeutics, Inc. 与百时美施贵宝已明确分工：百时美施贵宝将全面负责新药临床试验申请的提交工作，并主导后续所有开发阶段及全球商业化布局。这一合作模式凸显了双方在创新药物领域的战略协同，预计将加速相关疗法的研发进程与市场渗透。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JANX","BK4539"],"gpt_icon":0},{"id":"1107112538","title":"Janux Therapeutics, Inc. 将完成临床前开发至新药临床试验申请阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1107112538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107112538?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:06","pubTimestamp":1769083585,"startTime":"0","endTime":"0","summary":"作为合作计划的一部分，Janux Therapeutics, Inc. 将负责推进其项目的临床前开发工作，直至达到提交新药临床试验申请的标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","JANX"],"gpt_icon":0},{"id":"1198312367","title":"Janux Therapeutics有望获得总额约8亿美元的开发、监管及商业里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1198312367","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198312367?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:06","pubTimestamp":1769083573,"startTime":"0","endTime":"0","summary":"根据协议条款，Janux Therapeutics, Inc.有资格获得累计最高约8亿美元的开发、监管和商业里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","JANX","BK4139"],"gpt_icon":0},{"id":"1136546380","title":"Janux Therapeutics股价在盘前交易中下跌44.3%，因公司公布早期前列腺癌药物临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1136546380","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136546380?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:26","pubTimestamp":1764667569,"startTime":"0","endTime":"0","summary":"Janux Therapeutics股价在盘前交易中下跌44.3%，因公司公布早期前列腺癌药物临床试验数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JANX"],"gpt_icon":0},{"id":"1159090029","title":"Janux公布在转移性去势抵抗性前列腺癌的I期临床试验中令人鼓舞的疗效和安全性数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159090029","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159090029?lang=zh_cn&edition=full","pubTime":"2025-12-02 05:06","pubTimestamp":1764623171,"startTime":"0","endTime":"0","summary":"Janux公布在转移性去势抵抗性前列腺癌的I期临床试验中令人鼓舞的疗效和安全性数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JANX","BK4539"],"gpt_icon":0},{"id":"2568413922","title":"Janux Therapeutics, Inc.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568413922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568413922?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:09","pubTimestamp":1758118150,"startTime":"0","endTime":"0","summary":"北京时间2025年09月17日22时09分，Janux Therapeutics, Inc.股票出现波动，股价急速上涨5.04%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.63%。其相关个股中，Scisparc Ltd.、Cdt Equity Inc.、Cdt Equity Inc C/Wts 22/09/2028涨幅较大，Scisparc Ltd.、Cdt Equity Inc.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为5243.09%、3965.93%、263.80%，振幅较大的相关个股有Scisparc Ltd.、Cdt Equity Inc.、Vyome Holdings, Inc.，振幅分别为147.28%、39.76%、38.21%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，开发针对癌症的肿瘤激活免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917220910a4cbd4ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250917220910a4cbd4ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JANX","LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2517430499","title":"Janux Therapeutics, Inc.2024财年实现净利润-68.99百万美元，同比减少18.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517430499?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日，Janux Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-68.99百万美元，同比减少18.36%；其中营业收入为10.59百万美元，同比增加31.06%，每股基本收益为-1.28美元。从资产负债表来看，Janux Therapeutics, Inc.总负债38.74百万美元，其中短期债务1.75百万美元，资产负债比为0.28，流动比率为0.60。机构评级：截至2025年3月8日，当前有13家机构对Janux Therapeutics, Inc.目标价做出预测，其中目标均价为86.54美元，其中最低目标价为25.00美元，最高目标价为200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000225abed6693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000225abed6693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JANX","LENZ"],"gpt_icon":0},{"id":"2517694882","title":"Janux Therapeutics, Inc.盘中异动 早盘急速拉升5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517694882?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:39","pubTimestamp":1741185583,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时39分，Janux Therapeutics, Inc.股票出现波动，股价急速上涨5.47%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223944a260ca65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223944a260ca65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","JANX","BK4539"],"gpt_icon":0},{"id":"2516589677","title":"Janux Therapeutics, Inc.盘中异动 早盘大幅跳水5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516589677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516589677?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:31","pubTimestamp":1741098719,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时31分，Janux Therapeutics, Inc.股票出现异动，股价大幅跳水5.28%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223159a25f0476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223159a25f0476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JANX","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2516585562","title":"Scotiabank：维持Janux Therapeutics(JANX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由62.00美元调整至41.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516585562","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516585562?lang=zh_cn&edition=full","pubTime":"2025-03-01 07:47","pubTimestamp":1740786423,"startTime":"0","endTime":"0","summary":"Scotiabank：维持Janux Therapeutics(JANX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由62.00美元调整至41.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01074748470501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["JANX","LENZ"],"gpt_icon":0},{"id":"1136124682","title":"Janux Therapeutics 2024年第四季度GAAP每股收益$(0.36) 超出预期$(0.47)","url":"https://stock-news.laohu8.com/highlight/detail?id=1136124682","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136124682?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:38","pubTimestamp":1740692305,"startTime":"0","endTime":"0","summary":"Janux Therapeutics  报告季度每股亏损$，超出分析师一致预期的$，超过23.4%。相比去年同期每股亏损$，这是一个44%的下降。以上内容来自Benzinga Earnings专栏，原文如下：Janux $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 23.4 percent. This is a 44 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JANX","LENZ"],"gpt_icon":0},{"id":"2513576720","title":"Janux Therapeutics, Inc.盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513576720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513576720?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:54","pubTimestamp":1740408845,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时54分，Janux Therapeutics, Inc.股票出现波动，股价大幅下跌5.03%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，Pepgen Inc.、Telix Pharmaceutic、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为136.18%、55.56%、25.06%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225406962e9e7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225406962e9e7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX","BK4139","BK4539"],"gpt_icon":0},{"id":"2509238049","title":"Janux Therapeutics, Inc.盘中异动 早盘急速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509238049","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509238049?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:44","pubTimestamp":1738770244,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时44分，Janux Therapeutics, Inc.股票出现异动，股价急速拉升5.06%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.45%。其相关个股中，Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Oragenics Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为4054.20%、1197.54%、978.89%，振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028，振幅分别为86.20%、59.80%、54.05%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205234405abc38da0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205234405abc38da0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX","BK4539","BK4139"],"gpt_icon":0},{"id":"2508835463","title":"Janux Therapeutics, Inc.盘中异动 早盘股价大跌5.25%报39.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508835463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508835463?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:23","pubTimestamp":1738682607,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时23分，Janux Therapeutics, Inc.股票出现异动，股价大幅下挫5.25%。截至发稿，该股报39.86美元/股，成交量20.2631万股，换手率0.35%，振幅5.35%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.33%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204232327abc232e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204232327abc232e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","BK4139","JANX"],"gpt_icon":0},{"id":"2506874303","title":"Janux Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报46.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506874303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506874303?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:42","pubTimestamp":1737988923,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时42分，Janux Therapeutics, Inc.股票出现波动，股价大幅拉升5.10%。截至发稿，该股报46.36美元/股，成交量3.2984万股，换手率0.06%，振幅6.78%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.93%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224203a2316d37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224203a2316d37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JANX","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"1143280520","title":"异动解读 | 生物技术公司Janux Therapeutics盘中大跌5.26%,最新财报不佳或成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1143280520","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143280520?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:34","pubTimestamp":1737052472,"startTime":"0","endTime":"0","summary":"生物技术公司Janux Therapeutics(JANX.us)今日盘中大跌5.26%,引发投资者广泛关注。根据最新财报数据,该公司净利润亏损达2806万美元,每股收益为-0.51美元,可能是导致股价下跌的主要因素之一。\n\n此外,整个生物技术行业当日呈现整体下跌态势,跌幅达0.35%,为Janux Therapeutics股价下跌增添了一些压力。不过,目前仍无其他直接相关消息可解释该股今日出现如此大幅波动。\n\n市场机构方面,在16家参与评级的分析机构中,高达88%给予该股买入评级,看好其长期发展前景。后市如何走向或将取决于公司未来的基本面表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 生物技术公司Janux Therapeutics盘中大跌5.26%,最新财报不佳或成主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["JANX"],"gpt_icon":0},{"id":"2504946519","title":"Janux Therapeutics, Inc.盘中异动 下午盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504946519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504946519?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:18","pubTimestamp":1737051514,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日02时18分，Janux Therapeutics, Inc.股票出现波动，股价急速下挫5.08%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.35%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021834960636d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021834960636d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JANX","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2503758308","title":"Janux Therapeutics, Inc.盘中异动 急速下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503758308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503758308?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:44","pubTimestamp":1736779470,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时44分，Janux Therapeutics, Inc.股票出现波动，股价快速下挫5.26%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.06%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132244309864d883&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132244309864d883&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JANX","BK4539","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.januxrx.com","stockEarnings":[{"period":"1week","weight":0.0405},{"period":"1month","weight":-0.0244},{"period":"3month","weight":-0.6008},{"period":"6month","weight":-0.401},{"period":"1year","weight":-0.5748},{"period":"ytd","weight":-0.0138}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Janux Therapeutics, Inc.于2017年6月27日在特拉华州注册成立。该公司是一家创新的生物制药公司，开发基于该公司专有的肿瘤激活T细胞接合器（TRACTr）平台技术的下一代疗法，以更好地治疗癌症患者。该公司最初的重点是开发一类新的T细胞接合器（TCE），该公司的主要候选产品是针对临床验证的药物靶点设计的。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.012335},{"month":2,"riseRate":0.4,"avgChangeRate":0.856876},{"month":3,"riseRate":0,"avgChangeRate":-0.210851},{"month":4,"riseRate":0.75,"avgChangeRate":0.173971},{"month":5,"riseRate":0.25,"avgChangeRate":-0.113738},{"month":6,"riseRate":0.5,"avgChangeRate":-0.031968},{"month":7,"riseRate":0.8,"avgChangeRate":0.101052},{"month":8,"riseRate":0.4,"avgChangeRate":-0.03768},{"month":9,"riseRate":0.4,"avgChangeRate":-0.031046},{"month":10,"riseRate":0.8,"avgChangeRate":0.092219},{"month":11,"riseRate":0.4,"avgChangeRate":-0.026162},{"month":12,"riseRate":0.6,"avgChangeRate":-0.021325}],"exchange":"NASDAQ","name":"Janux Therapeutics, Inc.","nameEN":"Janux Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Janux Therapeutics, Inc.(JANX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Janux Therapeutics, Inc.(JANX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Janux Therapeutics, Inc.,JANX,Janux Therapeutics, Inc.股票,Janux Therapeutics, Inc.股票老虎,Janux Therapeutics, Inc.股票老虎国际,Janux Therapeutics, Inc.行情,Janux Therapeutics, Inc.股票行情,Janux Therapeutics, Inc.股价,Janux Therapeutics, Inc.股市,Janux Therapeutics, Inc.股票价格,Janux Therapeutics, Inc.股票交易,Janux Therapeutics, Inc.股票购买,Janux Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Janux Therapeutics, Inc.(JANX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Janux Therapeutics, Inc.(JANX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}